EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway

Enhong Chen, Qin Wang, Leisheng Wang, Zebo Huang, Dongjie Yang, Changyong Zhao, Wuqiang Chen, Shuo Zhang, Shuming Xiong, Youzhao He, Yong Mao, Hao Hu

Cancer Communications · 2025-09 · 45 (9) · 1162-1187

DOI: 10.1002/cac2.70045 ↗

At a glance

Journal article in Cancer Communications, published online on 2025-06-20. Written by Enhong Chen and 11 co-authors. Institution: Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, P. R. China. Major MEDLINE topics: Carcinoma, Pancreatic Ductal, Tumor Microenvironment, Pancreatic Neoplasms, Focal Adhesion Kinase 1. Cited 24 times so far (Crossref); 91 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Jiangsu Natural Science Foundation Project, Scientific Research Project of Jiangsu Provincial Health Commission, High-level talent training project of Wuxi Taihu Talent Plan.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

N‐acetyltransferase 10 (NAT10) was reported to be associated with the immune microenvironment in several cancers. However, it is not known in pancreatic ductal adenocarcinoma (PDAC). This study aimed to elucidate the roles and mechanisms of NAT10 in tumor malignancy and the tumor microenvironment (TME) in PDAC.

Methods

NAT10 expression and its role in tumor progression and clinical prognosis were analyzed using bioinformatics and functional assays. Downstream genes regulated by NAT10 and their underlying mechanisms were explored using acetylated RNA immunoprecipitation, quantitative polymerase chain reaction, RNA immunoprecipitation, and Western blotting. The role and mechanism of NAT10 in the PDAC TME were further explored using bioinformatics, single‐cell RNA sequencing, multiplexed immunofluorescence, and flow cytometry. The association between NAT10 and immunotherapeutic response was investigated in a mouse model by inhibiting the programmed cell death 1/programmed cell death ligand 1(PD‐1/PD‐L1) axis with a PD‐1/PD‐L1 binding inhibitor, Naamidine J.

Results

NAT10 was upregulated in PDAC tissues and cell lines, and was associated with poor progression‐free survival of PDAC patients. NAT10 promoted tumor progression by enhancing the mRNA stability of laminin β3 (LAMB3) via N4‐acetylation modification, thereby activating the focal adhesion kinase (FAK)/extracellular regulated protein kinases (ERK) pathway. NAT10 promoted subcutaneous tumor growth, increased the proportion of exhausted CD8 + T cells (CD8 + Tex), especially the intermediate CD8 + Tex subset, and decreased the proportion of cytotoxic CD8 + T cell (CD8 + Tc) subset in the PDAC TME. Naamidine J treatment significantly enhanced the proportion of CD8 + Tc subset and reduced the proportion of intermediate CD8 + Tex subset in mice bearing subcutaneous tumors with high NAT10 expression. Regarding the regulatory mechanism, NAT10 increased PD‐L1 expression and abundance in tumor cells by activating the LAMB3/FAK/ERK pathway, thereby reducing the cytotoxicity of CD8 + T cells. Inhibition of the PD‐1/PD‐L1 axis with Naamidine J retrieved CD8 + T cell cytotoxicity.

Conclusions

This study proposes a regulatory role of NAT10 in tumor progression and immune microenvironment via the LAMB3/FAK/ERK pathway in PDAC. These findings may favor the selection of candidates who may benefit from immunotherapy, optimize current therapeutic strategies, and improve the clinical prognosis of PDAC patients.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Pancreatic DuctalTumor MicroenvironmentPancreatic NeoplasmsFocal Adhesion Kinase 1LamininAnimalsHumansMiceCell Line, TumorMAP Kinase Signaling SystemAcetylationDisease ProgressionB7-H1 AntigenGene Expression Regulation, NeoplasticFemaleMale

Author keywords

CD8+ T cell exhaustionLAMB3NAT10PD‐1/PD‐L1pancreatic ductal adenocarcinoma

Substances

Focal Adhesion Kinase 1LamininPTK2 protein, humanB7-H1 AntigenCD274 protein, human

Authors and institutions

  • Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, P. R. China.
  • School of Medicine, Jiangnan University, Wuxi, Jiangsu, P. R. China.
  • Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, P. R. China.
  • Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, P. R. China.
  • Hepatobiliary and Pancreatic Surgery, The Third Hospital Affiliated to Nantong University, Wuxi, Jiangsu, P. R. China.
  • Medical School, Nantong University, Nantong, Jiangsu, P. R. China.

Funding

  • Jiangsu Natural Science Foundation Project
  • Scientific Research Project of Jiangsu Provincial Health Commission
  • High-level talent training project of Wuxi Taihu Talent Plan
  • Clinical Medical Research Project of the Affiliated Hospital of Jiangnan University
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province

Cite

APA

Chen, E., Wang, Q., Wang, L., Huang, Z., Yang, D., Zhao, C., Chen, W., Zhang, S., Xiong, S., He, Y., Mao, Y., & Hu, H. (2025). NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway. Cancer Communications, 45(9), 1162-1187. https://doi.org/10.1002/cac2.70045

Vancouver

Chen E, Wang Q, Wang L, Huang Z, Yang D, Zhao C, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway. Cancer Communications. 2025;45(9):1162-1187. doi:10.1002/cac2.70045

BibTeX
@article{Chen2025,
  author = {Chen, Enhong and Wang, Qin and Wang, Leisheng and Huang, Zebo and Yang, Dongjie and Zhao, Changyong and Chen, Wuqiang and Zhang, Shuo and Xiong, Shuming and He, Youzhao and Mao, Yong and Hu, Hao},
  title = {NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4‐acetylated LAMB3‐mediated FAK/ERK pathway},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {9},
  pages = {1162--1187},
  doi = {10.1002/cac2.70045}
}
Start for free →